Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia

Hypertension

Volumn 64, Issue 4, 2014, Pages 833-838

  Burwick, Richard M ^a   Easter, Sarah Rae ^b   Dawood, Hassan Y ^b   Yamamoto, Hidemi S ^b   Fichorova, Raina N ^b   Feinberg, Bruce B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Complement membrane attack complex; Complement system proteins; Preeclampsia; Pregnancy

Indexed keywords

ACUTE PHASE PROTEIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; EPIDERMAL GROWTH FACTOR; HAVCR1 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN; OSTEOPONTIN; TAMM HORSFALL GLYCOPROTEIN; VIRUS RECEPTOR;

ADULT; ALBUMINURIA; CASE CONTROL STUDY; COMPLEMENT ACTIVATION; FEMALE; HUMAN; IMMUNOLOGY; INJURIES; KIDNEY PROXIMAL TUBULE; PATHOLOGY; PREECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX; URINE;

ACUTE-PHASE PROTEINS; ADULT; ALBUMINURIA; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; KIDNEY TUBULES, PROXIMAL; LIPOCALINS; MEMBRANE GLYCOPROTEINS; OSTEOPONTIN; PRE-ECLAMPSIA; PREGNANCY; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; SEVERITY OF ILLNESS INDEX; UROMODULIN;

EID: 84914155680     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03456     Document Type: Article

References (73)

1. Spargo BH, McCartney C, Winemiller R. Glomerular capillary endotheliosis in toxemia of pregnancy. Arch Pathol. 1959;13: 593-599.
2. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18: 2281-2284.
3. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, Rose CH, Gavrilova L, Craigo P, Bailey KR, Achenbach J, Schiffer M, Grande JP. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196: 320.e1-320.e7.
4. Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, Turner ST, Hayman SR, White WM, Brost BC, Rose CH, Grande JP, Garovic VD. Podocyturia predates proteinuria and clinical features of preeclampsia: Longitudinal prospective study. Hypertension. 2013;61: 1289-1296.
5. Irving FC. A study of five hundred consecutive cases of pre-eclampsia. Can Med Assoc J. 1939;40: 137-140.
6. Hayashi M, Ueda Y, Hoshimoto K, Ota Y, Fukasawa I, Sumori K, Kaneko I, Abe S, Uno M, Ohkura T, Inaba N. Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. Am J Kidney Dis. 2002;39: 392-400.
7. Gibb DM, Tomlinson PA, Dalton NR, Turner C, Shah V, Barratt TM. Renal tubular proteinuria and microalbuminuria in diabetic patients. Arch Dis Child. 1989;64: 129-134.
8. Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: Glomerulotubular communication in IgA nephropathy. Kidney Int. 2005;67: 602-612.
9. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol. 2012;32: 452-462.
10. Johnson RK, Sarmarapungavan D, Parasuraman RK, Maine G, Rooney MT, Wolforth SC, Reddy GH, Cohn SR, Dumler F, Rocher LL, Li W, Zhang PL. Acute tubular injury is an important component in type I acute antibody-mediated rejection. Transplant Proc. 2013;45: 3262-3268.
11. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27: 195-207.
12. Rosser ML, Katz NT. Preeclampsia: An obstetrician's perspective. Adv Chronic Kidney Dis. 2013;20: 287-296.
13. August P. Preeclampsia: A "nephrocentric" view. Adv Chronic Kidney Dis. 2013;20: 280-286.
14. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol. 1989;161: 1200-1204.
15. Redman CW, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1): 499-506.
16. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet. 2002; 99: 67-75.
17. Haeger M, Unander M, Norder-Hansson B, Tylman M, Bengtsson A. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 1992;79: 19-26.
18. Haeger M, Unander M, Andersson B, Tarkowski A, Arnestad JP, Bengtsson A. Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Acta Obstet Gynecol Scand. 1996;75: 695-701.
19. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol. 2003;59: 153-160.
20. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: Tipping the balance of complement activation in pregnancy. Hypertension. 2013;62: 1040-1045.
21. Baldamus CA, Galaske R, Eisenbach GM, Krause HP, Stolte H. Glomerular protein filtration in normal and nephritic rats. A micropuncture study. Contrib Nephrol. 1975;1: 37-49.
22. Stolte H, Schurek HJ, Alt JM. Glomerular albumin filtration: A comparison of micropuncture studies in the isolated perfused rat kidney with in vivo experimental conditions. Kidney Int. 1979;16: 377-384.
23. Wibell L. The serum level and urinary excretion of beta2-microglobulin in health and renal disease. Pathol Biol (Paris). 1978;26: 295-301.
24. Nakajima Y, Hoshi F, Higuchi S, Kawamura S. Determination of bovine beta2-microglobulin and albumin in urine by a reversed-phase high-performance liquid chromatography. J Vet Med Sci. 1999;61: 725-729.
25. Hoshi F, Nagai D, Nakajima Y, Higuchi S, Kawamura S. Purification of bovine urinary beta2-microglobulin and its biochemical characteristics. J Vet Med Sci. 2000;62: 867-874.
26. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta. 2002;323: 121-128.
27. Togashi Y, Imura N, Miyamoto Y. Urinary cystatin C as a renal biomarker and its immunohistochemical localization in anti-GBM glomerulonephritis rats. Exp Toxicol Pathol. 2013;65: 1137-1143.
28. Gesualdo L, Di Paolo S, Calabró A, Milani S, Maiorano E, Ranieri E, Pannarale G, Schena FP. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: An immunohistochemical and in situ hybridization study. Kidney Int. 1996;49: 656-665.
29. Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int. 2000;58: 182-192.
30. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury. J Biol Chem. 1998;273: 4135-4142.
31. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14: 2534-2543.
32. Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury-where do we stand today? Nephrol Dial Transplant. 2011;26: 762-764.
33. Gokhale JA, Glenton PA, Khan SR. Localization of tamm-horsfall protein and osteopontin in a rat nephrolithiasis model. Nephron. 1996;73: 456-461.
34. Verhulst A, Persy VP, Van Rompay AR, Verstrepen WA, Helbert MF, De Broe ME. Osteopontin synthesis and localization along the human nephron. J Am Soc Nephrol. 2002;13: 1210-1218.
35. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int. 2003;63: 543-553.
36. Hoyer JR, Sisson SP, Vernier RL. Tamm-Horsfall glycoprotein: Ultrastructural immunoperoxidase localization in rat kidney. Lab Invest. 1979;41: 168-173.
37. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Much ado about nothing? Am J Obstet Gynecol. 1990;162: 311-316.
38. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. http: //www. acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy. Accessed December 23, 2013.
39. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: The need for a more pathophysiological approach. Obstet Gynecol. 2010;115(2 Pt 1): 365-375.
40. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111: 649-658.
41. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350: 672-683.
42. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, Rose CH, Gavrilova L, Craigo P, Bailey KR, Achenbach J, Schiffer M, Grande JP. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196: 320.e1-320.e7.
43. Ramjee G, Coovadia HM, Adhikari M. Direct and indirect tests of pore size and charge selectivity in nephrotic syndrome. J Lab Clin Med. 1996;127: 195-199.
44. Vehaskari VM, Root ER, Germuth FG Jr, Robson AM. Glomerular charge and urinary protein excretion: Effects of systemic and intrarenal polycation infusion in the rat. Kidney Int. 1982;22: 127-135.
45. Gekle M. Renal tubule albumin transport. Annu Rev Physiol. 2005;67: 573-594.
46. Nejat M, Hill JV, Pickering JW, Edelstein CL, Devarajan P, Endre ZH. Albuminuria increases cystatin C excretion: Implications for urinary biomarkers. Nephrol Dial Transplant. 2012; 27 Suppl 3: 96-103.
47. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008;118: 1657-1668.
48. Peng Q, Li K, Smyth LA, Xing G, Wang N, Meader L. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012; 23: 1474-1485.
49. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105: 1363-1371.
50. Zhang Q, Davis KJ, Hoffmann D, Vaidya VS, Brown RP, Goering PL. Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats. Biomark Med. 2014;8: 85-94.
51. Madsen MG, N?rregaard R, Palmfeldt J, Olsen LH, Fr?ki?r J, J?rgensen TM. Urinary NGAL, cystatin C, ß2-microglobulin, and osteopontin significance in hydronephrotic children. Pediatr Nephrol. 2012;27: 2099-2106.
52. Kalantari S, Rutishauser D, Samavat S, Nafar M, Mahmudieh L, Rezaei- Tavirani M, Zubarev RA. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS One. 2013;8: E80830.
53. Sinha V, Vence LM, Salahudeen AK. Urinary tubular protein-based biomarkers in the rodent model of cisplatin nephrotoxicity: A comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury. J Investig Med. 2013;61: 564-568.
54. Zhou J, Chen Y, Liu Y, Shi S, Wang S, Li X, Zhang H, Wang H. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy. PLoS One. 2013;8: E71023.
55. Bleyer AJ, Zivná M, Kmoch S. Uromodulin-associated kidney disease. Nephron Clin Pract. 2011;118: C31-c36.
56. Woodson BW, Wang L, Mandava S, Lee BR. Urinary cystatin C and NGAL as early biomarkers for assessment of renal ischemia-reperfusion injury: A serum marker to replace creatinine? J Endourol. 2013;27: 1510-1515.
57. Tasanarong A, Hutayanon P, Piyayotai D. Urinary Neutrophil Gelatinase- Associated Lipocalin predicts the severity of contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. BMC Nephrol. 2013;14: 270.
58. Mathiesen ER, Nexø E, Hommel E, Parving HH. Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy. Diabet Med. 1989;6: 121-126.
59. Taira T, Yoshimura A, Iizuka K, Iwasaki S, Ideura T, Koshikawa S. Urinary epidermal growth factor levels in patients with acute renal failure. Am J Kidney Dis. 1993;22: 656-661.
60. Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA, Bloemenkamp KW, Baelde HJ. Preeclampsia is characterized by placental complement dysregulation. Hypertension. 2012;60: 1332-1337.
61. Rampersad R, Barton A, Sadovsky Y, Nelson DM. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta. 2008;29: 855-861.
62. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, Edwin S, Kim YM, Hong JS, Mazor M. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17: 239-245.
63. Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. Am J Obstet Gynecol. 1997;177: 57-65.
64. Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, Kaufmann P. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta. 2003;24: 181-190.
65. Kerjaschki D, Schulze M, Binder S, Kain R, Ojha PP, Susani M, Horvat R, Baker PJ, Couser WG. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol. 1989;143: 546-552.
66. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000;11: 700-707.
67. vanWerkhoven MB, Damman J, Daha MR, Krikke C, van Goor H, van Son WJ, Hillebrands JL, van Dijk MC, Seelen MA. Novel insights in localization and expression of C5aR and C5L2 under native and posttransplant conditions. Mol Immunol. 2013; 53: 237-245.
68. Fayyazi A, Scheel O, Werfel T, Schweyer S, Oppermann M, Götze O, Radzun HJ, Zwirner J. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology. 2000;99: 38-45.
69. Burwick RM, Feinberg BB. Eculizumab for the treatment of severe preeclampsia/ HELLP syndrome. Placenta. 2013; 34: 201-203.
70. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360: 542-544.
71. Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: A case report. Pediatrics. 2012;130: E1385-e1388.
72. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364: 2561-2563.
73. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010; 362: 1744-1745.